8-K current report · filed Aug 6, 2026

Biomarin Pharmaceutical Inc (BMRN) 8-K Current Report: August 6, 2026

Item 2.02Item EX-99.1BMRN overview

Short answer

Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced for quarter ended June 30, 2026.

Biomarin Pharmaceutical Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Full operating metrics and management commentary available in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $990M, up 20% year over year, led by Amicus products GALAFOLD and POMBILITI + OPFOLDA plus VOXZOGO growth
  • GAAP net income fell 81% to $45M, reflecting Amicus integration costs, amortization, financing interest and inventory step-up charges
  • 2026 revenue guidance raised to $3.875B-$3.925B, while VOXZOGO guidance increased to $1.0B-$1.05B
  • Non-GAAP diluted EPS guidance raised to $4.90-$5.10, despite approximately $200M annualized Amicus financing interest expense
  • Amicus integration targets approximately $220M non-GAAP cost synergies by 2028, with gross leverage below 2.5 times targeted by mid-2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Biomarin Pharmaceutical Inc 8-K filings

Get the next BMRN 8-K as it lands

Follow BMRN for push alerts, or ask the research agent what this filing means.